Experienced industry veteran joins OmniComm’s executive team to drive technology operations for leading electronic data capture (EDC) company.
FT. Lauderdale, FL-June 2, 2008-OmniComm Systems, Inc., a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that Thomas Wells has joined OmniComm to spearhead technology operations for the rapidly growing eClinical solutions company. Wells brings a strong pharmaceutical and health care background to the position. He will be responsible for driving strategy and delivering business processes and systems for product development as OmniComm delivers integrated solutions to meet industry demand.
Prior to joining OmniComm, Wells served as director, research and development informatics at Amgen, Inc. In his role at Amgen, he managed global teams that implemented and supported all of Amgen’s development systems. The teams implemented over 50 new clinical trials annually and maintained approximately 100+ trials in both EDC and Oracle Clinical. In addition, part of his responsibilities included expanding the global EDC program into large Phase II and III clinical trials. Prior to Wells’ tenure at Amgen, he worked for Integrium, a clinical research organization, as director, information technology where he developed and implemented all clinical trials management systems and all data management systems to fully integrate and interface with OCR, EDC, and other external sources. He also partnered with QA and was responsible for all sponsor audits.
Before joining Integrium, Wells served as senior systems architect for Ultralink Inc., a Web-based health care system and EDI solutions company. Prior to that, he held positions with Cocensys, Inc, a CNS biopharmaceutical company, Specialized Clinical Services, Inc., Long Beach Genetics, Inc., and Eastman Kodak, Clinical Products Division.
“Thomas’s exceptional industry credentials are a welcome addition to the OmniComm team and we look forward to benefiting from his strategic vision for technical operations," said Cornelis F. Wit, chief executive officer for OmniComm. “He brings a plethora of industry knowledge and experience that will help OmniComm bring to fruition the next generation eClinical products and solutions that our clients demand.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.